安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- De Novo Metastatic Prostate Cancer: Are We Moving toward a . . .
De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the
- Survival in Patients With De Novo Metastatic Prostate Cancer
Overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) has improved in clinical trials over the last 20 years 1,2 It is unclear whether new treatments have translated to improvements in survival rates in clinical practice We sought to quantify trends in OS among patients with newly diagnosed de novo (synchronous) mHSPC
- Management of de Novo Metastatic Hormone-Sensitive Prostate . . .
Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and Clinical Oncology aimed to create a consensus on radiation therapy indication in de novo metastatic hormone-sensitive prostate cancer both on primary tumor and metastatic sites
- Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era . . .
The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant prostate cancer (mCRPC) Both disease phases hold similar In this review, we take stock of the current landscape of treatment for metastatic hormone-sensitive prostate cancer, including
- Updated treatment recommendations for prostate cancer from . . .
ADT–docetaxel–abiraterone–prednisone is recommended as first-line treatment for fit men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with multiple bone metastases (>3) or visceral metastases [I, B; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1 1 score: 4; regimen not EMA or FDA approved]
|
|
|